Cytek cut from buy to sell by Goldman Sachs
Goldman Sachs has downgraded Cytek Biosciences (NASDAQ:CTKB) to sell from buy, citing increased competition and end market challenges. The investment bank said it believes consensus expectations for a 2025 recovery are "too steep,
Goldman Sachs cuts Comcast stock target to $44, maintains buy
Goldman Sachs analyst Michael Ng revised the price target on Comcast Corporation (NASDAQ:CMCSA) shares, reducing it from $50.00 to $44.00, while still recommending the stock as a Buy. With a market capitalization of $126 billion and trading near its 52-week low,
Last Minute Thought: Goldman Sachs Chimes In on Tesla Stock Ahead of Earnings
Tesla (NASDAQ:TSLA) will be under the Street’s microscope today with the EV giant slated to release 4Q24 results after the close. Investors
Why Goldman Sachs says investors should buy the dip in U.S. tech stocks
Monday’s trillion-dollar stock-market wipeout will be remembered as an opportunity to scoop up shares of some of the most valuable U.S. companies at a discount, according to a team of equity strategists at Goldman Sachs Group.
Goldman Sachs cuts Cytek Biosciences stock rating to sell
Goldman Sachs analyst Matthew Sykes downgraded Cytek Biosciences Inc (NASDAQ:CTKB) stock rating from Buy to Sell and reduced the price target to $4.50 from the previous $7.00. The downgrade reflects concerns over the company's market position and sales outlook.
All Eyes on Microsoft Stock Ahead of Earnings; Here’s What Goldman Sachs Expects
Microsoft (NASDAQ:MSFT) has lagged behind the NASDAQ over the past year but is off to a strong start in 2025, outperforming the broader market.
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna down as Goldman Sachs downgrades on revenue outlook
Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Goldman's downgrade comes days after the Cambridge,
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna stock drops as Goldman Sachs cuts rating
Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs (NYSE:GS) cut its rating on the stock to Neutral from Buy.
Goldman Sachs resumes coverage on Expand Energy with buy, cuts Occidental to sell
Goldman Sachs reinstated coverage on Expand Energy Corp (NASDAQ:EXE) with a "Buy" rating and a $121 price target, citing operational efficiency and strategic exposure to key natural gas basins ...
The bears never stood a chance — this month. But Goldman strategist says he’ll turn ‘tactical bear’ after Valentine’s.
Between you-only-live-once retail traders, big corporates buying back their stock and retirement allocation demand, the bears ...
Cryptopolitan on MSN1d
Goldman Sachs: DeepSeek is triggering a correction, not a bear market
The report comes as tech stocks, led by the Magnificent Seven—think Apple, Microsoft, Google, and their mega-cap friends—take ...
Goldman Sachs maintains LPL Financial stock buy rating, $405 target
Goldman Sachs reaffirmed its Buy rating and $405.00 price target for LPL Financial Holdings (NASDAQ:LPLA), following the company's fourth-quarter earnings report. LPL Financial reported earnings per ...
Goldman Sachs's 3 takeaways from the Fed
Treasury yield is hovering just above a six-week low around 4.50% as investors continue to digest Wednesday’s monetary policy update from the Federal Reserve. The U.S. central bank left interest rates ...